Therefore, activating more than one PPAR family member by a suitable exogenous ligand (dual- or pan-agonist) could represent an effective therapy against several metabolic alterations, such as hypertriglyceridemia, NAFLD, even fibrosis, and inflammation. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.